NZ739408A - Meditopes and meditope-binding antibodies and uses thereof - Google Patents
Meditopes and meditope-binding antibodies and uses thereofInfo
- Publication number
- NZ739408A NZ739408A NZ739408A NZ73940812A NZ739408A NZ 739408 A NZ739408 A NZ 739408A NZ 739408 A NZ739408 A NZ 739408A NZ 73940812 A NZ73940812 A NZ 73940812A NZ 739408 A NZ739408 A NZ 739408A
- Authority
- NZ
- New Zealand
- Prior art keywords
- phenylalanine
- acid
- containing residue
- cys
- ala
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Discloses an isolated meditope-enabled antibody or fragment thereof, comprising: a heavy chain variable (VH) region, a heavy chain constant region (CH) or portion thereof, a light chain variable (VL) region antibodies and meditopes bound bythe antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.
Description
PES AND MEDITOPE-BINDING ANTIBODIES AND USES THEREOF
PRIORITY
Claims (1)
1. A complex comprising: (i) a meditope-binding dy or fragment thereof comprising: a pe binding site; a heavy chain le (VH) region and a light chain variable (VL) region, wherein: the VL region comprises an amino acid sequence comprising an isoleucine or leucine at position 10, a threonine, serine, or aspartate at position 40, a residue other than glycine at position 41, an isoleucine at position 83 and an aspartate or asparagine at position 85, according to Kabat numbering; the VH region comprises an amino acid ce comprising a serine or proline at position 40 and an isoleucine, tyrosine, methionine, phenylalanine, or tryptophan at position 89, according to Kabat numbering; and (ii) a meditope-peptide having the formula: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12 (Formula I) wherein: X1 = Cys, Gly, β-alanine, diaminopropionic acid, β-azidoalanine, or null; X2 = Gln or null; X3 = Phe, Tyr, β-β’-diphenyl-Ala, His, Asp, 2-bromo-L-phenylalanine, 3-bromo-L- phenylalanine, or 4-bromo-L-phenylalanine, Asn, Gln, a modified Phe, a hydratable carbonylcontaining residue; or a boronic acid-containing residue; X4 = Asp or Asn; X5 = Leu; β-β’-diphenyl-Ala; Phe; a non-natural analog of phenylalanine, phan, or tyrosine; a hydratable yl-containing residue; or a boronic acid-containing residue; X6 = Ser or Cys; X7 = Thr or Ser or Cys; X8 = Arg, a modified Arg, or a able carbonyl or boronic acid-containing residue; X9 = Arg, Ala; X10 = Leu, Gln, Glu, β-β’-diphenyl-Ala; Phe; a non-natural analog of phenylalanine, phan, or ne; a hydratable carbonyl-containing residue; or a boronic acid-containing residue; X11= Lys; and X12 = Cys, Gly, 7-aminoheptanoic acid, β-alanine, diaminopropionic acid, propargylglycine, isoaspartic acid, or null, wherein: the modified Arg has a structure of the formula shown in
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39155810P | 2010-10-08 | 2010-10-08 | |
| US13/270,207 US8658774B2 (en) | 2010-10-08 | 2011-10-10 | Meditopes and related meditope-monoclonal antibody delivery systems, synthesis and therapeutic uses thereof |
| PCT/US2011/055656 WO2012048332A2 (en) | 2010-10-08 | 2011-10-10 | A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use |
| US201261597708P | 2012-02-10 | 2012-02-10 | |
| NZ72205412 | 2012-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ739408A true NZ739408A (en) | 2022-08-26 |
Family
ID=83229136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ739408A NZ739408A (en) | 2010-10-08 | 2012-04-10 | Meditopes and meditope-binding antibodies and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ739408A (en) |
-
2012
- 2012-04-10 NZ NZ739408A patent/NZ739408A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266893A (en) | Meditopes and meditope-binding antibodies and uses thereof | |
| RU2012111708A (en) | HUMANIZED ANTIBODIES TO CDCP1 | |
| NZ599140A (en) | Antibodies that specifically bind to the epha2 receptor | |
| PH12014502419A1 (en) | Specific binding proteins and uses thereof | |
| NZ595825A (en) | Antibody containing igg2 having amino acid mutation introduced therein | |
| WO2015012904A3 (en) | Antibody-sn-38 immunoconjugates with a cl2a linker | |
| SI2771031T1 (en) | Humanized antibodies that recognize alpha-synuclein | |
| PE20091352A1 (en) | COMPOSITION INCLUDING ANTIBODY THAT IS FIXED TO DOMAIN II OF HER2, AND ITS ACID VARIANTS | |
| DOP2013000029A (en) | PEPTIDIC ANTIBODIES BETA AMILOIDE ANTI-N3PGLU AND USES OF THE SAME | |
| NZ708528A (en) | Anti-ceacam5 antibodies and uses thereof | |
| NZ612161A (en) | Radiolabled her2 binding peptides | |
| TN2010000298A1 (en) | Novel insulin derivatives having an extremely delayed time-action profile | |
| UA103015C2 (en) | Novel insulin derivatives having an extremely delayed time-action profile | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| UA102867C2 (en) | Anti cxcr4 antibodies and their use for the treatment of cancer | |
| WO2005098435A3 (en) | Peptides and peptidomimetics binding to cd23 | |
| WO2011041319A8 (en) | Specific binding proteins and uses thereof | |
| PE20121702A1 (en) | BINDING PROTEINS CD127 | |
| RU2015103816A (en) | CELLING PEPTIDES IN THE CELL, THE TARGET OF WHICH IS THE eIF4E | |
| NZ612327A (en) | Her2 binding peptides labelled with a 18f - containing organosilicon compound | |
| EA200970694A1 (en) | PEHYLATED Fab ANTIBODY FRAGMENTS TO Aβ PEPTIDE | |
| IL189452A0 (en) | Therapy with cd4 binding peptides and radiation | |
| NZ594198A (en) | Neil3 peptides and vaccines including the same | |
| CA2725873A1 (en) | Monoclonal antibodies to basic fibroblast growth factor | |
| NZ610091A (en) | Antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 9 YEARS UNTIL 10 APR 2025 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20230211 |